Frontlight ResearchEarly access
CompletedPhase 3
Study of Dexycu in Treating Intraocular Inflammation
Key facts
- Who runs it
- Ocumension Therapeutics (Shanghai) Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 285 people enrolled
- Started
- 22 Aug 2022
- Ended
- 9 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dexycu
- Placebo
- Record updated
- 26 August 2024
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- The patient must provide written informed consent by signing the Informed Consent approved by the Institutional Review Board (IRB)
- Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation
- The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 in the study eye and better than 20/200 in the fellow eye
- The patient must be considered by the Investigator to have visual acuity potential. greater than 20/30 in the study eye
- The patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology
- A female patient of childbearing potential must have a negative pregnancy test on Day 0 and be using an effective method of birth control from Screening for the duration of the study
- The patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel
Who cannot take part
- Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0
- Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening
- Patients who have received any intravitreal corticosteroid delivery vehicle (e.g.,Retisert, Ozurdex, Iluvien) in the study eye at any time
- Patients who anticipate requiring treatment with any corticosteroids( by any route,except inhalation), during the study
- Patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye)
- Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to Day 0
- Patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening
- Patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening
- Patients with planned intraocular or laser surgery in the study eye for the duration of the study
- Patients who have received any prior intravitreal injections in the study eye
- Patients with ocular hypertension with an IOP in the study eye > 21 mm Hg at Screening with or without treatment with anti-glaucoma monotherapy
- Patients with ocular hypertension receiving treatment with two or more anti-glaucoma Medications
- Patients treated with any investigational product within 30 days prior to screening or patients enrolled previouslyc study
- Patients with an allergy or hypersensitivity to dexamethasone
- Patients with a history of chronic uveitis from any cause in either eye
- Patients with any signs of intraocular inflammation in either eye at screening
- Patients with evidence of corneal abnormality or dystrophy (e.g. opacities, guttae,clouding, etc.) or an inability to obtain an acceptable specular micrograph at Screening
- Patients with glaucomatous optic neuropathy or glaucomatous visual field loss in either eye
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of inflammation associated with cataract surgery.
The 2 groups in the trial
- Dexamethasone intraocular injectionTreatment being tested
Dexamethasone implant single injection in the treatment eye after cataract surgery.
Treatment: Dexycu
- PlaceboPlacebo, for comparison
Blank placebo single injection in the treatment eye after cataract surgery.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3,Prospective, Randomized, Double-masked, Placebo-controlled, Parallel Study to Evaluate the Efficacy, PK and Safety of 9% Dexamethasone Intraocular Injection for the Treatment of Inflammation Associatedwith Cataract Surgery
- Record updated
- 26 August 2024